Literature DB >> 6868004

The half life of factor XIII in the management of inherited deficiency.

J D Fear, K J Miloszewski, M S Losowsky.   

Abstract

Following the injection of a large dose of factor XIII concentrate the in vivo half life of factor XIII was estimated in a patient with inherited deficiency. Factor XIII activity and enzyme concentration were measured quantitatively, and a qualitative assessment of the crosslinking of fibrin was also made for upto 6 weeks after the injection. The half life was found to be about 9--10 days. This is longer than most previous reports suggest. An explantation for this finding is offered. The relevance of the long half life of factor XIII to the prophylactic treatment of patients with inherited deficiency is demonstrated.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6868004

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  3 in total

1.  Hereditary factor XIII deficiency.

Authors:  A P Patel; M Chandy; P Raghupathy; C Kirubakaran; U Khanduri
Journal:  Indian J Pediatr       Date:  1993 May-Jun       Impact factor: 1.967

2.  Cre/lox Studies Identify Resident Macrophages as the Major Source of Circulating Coagulation Factor XIII-A.

Authors:  Cora M L Beckers; Kingsley R Simpson; Kathryn J Griffin; Jane M Brown; Lih T Cheah; Kerrie A Smith; Jean Vacher; Paul A Cordell; Mark T Kearney; Peter J Grant; Richard J Pease
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-06-08       Impact factor: 8.311

Review 3.  Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency?

Authors:  Wolfgang Korte
Journal:  J Blood Med       Date:  2014-07-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.